3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Polycythemia Vera
6
Thrombocythemia, Essential
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Myeloproliferative Disorders
2
Melanoma
2
Solid Cancers
1
Skin Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasms
1
Neoplasm of Uncertain Malignant Potential
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Acute
1
Hepatitis C, Chronic
1
Glioma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Blast Crisis
1
Interventions
Cyclophosphamide
216
Methotrexate
140
Cytarabine
131
Vincristine
110
fludarabine phosphate
103
Peripheral Blood Stem Cell Transplantation
98
Filgrastim
92
Etoposide
92
Dexamethasone
89
Mycophenolic Acid
71
Doxorubicin
70
Whole-Body Irradiation
67
Mercaptopurine
66
Busulfan
65
Tacrolimus
64
Radiotherapy
63
Cyclosporine
62
Prednisone
55
Daunorubicin
53
pegaspargase
51
Asparaginase
51
Rituximab
48
fludarabine
47
Granulocyte Colony-Stimulating Factor
46
Melphalan
45
Antilymphocyte Serum
43
Clofarabine
42
Calcium Dobesilate
38
Methylprednisolone
36
Leucovorin
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
peginterferon alfa-2a
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled